Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

271

Enrollment

INDUSTRY

Sponsor class

Conditions

Virus, Zika
Zika Virus Disease
Flavivirus Infections
Healthy Participants

Interventions

DRUG: Placebo
BIOLOGICAL: PIZV

Sponsor

Takeda